No profile data available.
Mineralys Therapeutics, Inc. (MLYS) is a healthcare company in the blood vessel treatment pharmaceuticals industry, based in Radnor, United States, with about 76 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$154.65 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $2.06 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
Mineralys Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$2.06 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood vessel treatment pharmaceuticals) include United Therapeutics Corporation (UTHR), Liquidia Corporation (LQDA), Palvella Therapeutics, Inc. (PVLA), Gossamer Bio, Inc. (GOSS).